PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32508327-4	2020	OBJECTIVE: To report additional safety and exploratory efficacy data for continued open-label use of 45 mg BID pridopidine at 48 and 60 months.	pridopidine	111-122	BH3 interacting domain death agonist	Homo sapiens	107-110	
32508327-13	2020	CONCLUSION: The 45 mg BID pridopidine dosage remained safe and tolerable over 60 months.	pridopidine	26-37	BH3 interacting domain death agonist	Homo sapiens	22-25	
32508327-15	2020	Results are consistent with data reported from the recent Phase 2 PRIDE-HD trial showing less functional decline in the pridopidine 45 mg BID treated group at 52 weeks.	pridopidine	120-131	BH3 interacting domain death agonist	Homo sapiens	138-141	
33164941-6	2020	RESULTS: The pridopidine 45 mg bid dosage demonstrated a beneficial effect on TFC for the entire population at week 52 of 0.87 (nominal p = 0.003).	pridopidine	13-24	BH3 interacting domain death agonist	Homo sapiens	31-34	
33164941-9	2020	Responder analyses showed pridopidine 45 mg bid reduced the probability of TFC decline in early HD patients at Week 52 (nominal p = 0.02).	pridopidine	26-37	BH3 interacting domain death agonist	Homo sapiens	44-47	
33164941-10	2020	CONCLUSION: Pridopidine 45 mg bid results in a nominally significant reduction in TFC decline at 52 weeks compared to placebo, particularly in patients with early-stage HD.	pridopidine	12-23	BH3 interacting domain death agonist	Homo sapiens	30-33